Indications
Genib is used as the first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours carry epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as confirmed by an FDA-approved test.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Gefitinib reversibly inhibits the kinase activity of wild-type EGFR and certain of its activating mutations, preventing autophosphorylation of tyrosine residues linked to the receptor. This blocks further downstream signalling and stops EGFR-dependent cell proliferation. Gefitinib binds more strongly to EGFR carrying an exon 19 deletion or the exon 21 point mutation L858R than it does to wild-type EGFR. It also inhibits IGF and PDGF-mediated signalling at clinically relevant concentrations, though its effects on other tyrosine kinase receptors have not been fully characterized.
Pregnancy & Breastfeeding
There are no adequate, well-controlled studies of Gefitinib in pregnant women. If a woman uses Gefitinib during pregnancy, or becomes pregnant while taking it, she should be told about the possible harm to the unborn baby and the chance that the pregnancy could be lost. It is not known whether Gefitinib passes into breast milk. Because it could cause serious side effects in a nursing baby, mothers should be advised to stop breastfeeding while they are on Gefitinib.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.